Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
sabato, ottobre 03
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
BioMarin Pharmaceutical Inc
BMRN
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$57.18
-1.26
-2.16%
Ult. Agg.: Oct 2, 7:14 PM
$57.34
-1.10
-1.88%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
BioMarin Pharmaceutical Financials
BioMarin Pharmaceutical (BMRN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
BioMarin Pharmaceutical Raises FY2026 Adj EPS Guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 Est; Raises FY2026 Sales Guidance from $3.825B-$3.925B to $3.875B-$3.925B vs $3.875B Est
BioMarin Pharmaceutical (NASDAQ:BMRN) raises FY2026 Adj EPS guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 analyst estimate. Raises FY2026 sales outlook from $3.825 billion-$3.925 billion to $3.875 billion-$3.925
Benzinga Newsdesk
PRO
Biomarin Pharmaceutical Q2 Adj. EPS $1.20 Beats $0.69 Estimate, Sales $990.000M Beat $926.908M Estimate
Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $1.20 per share which beat the analyst consensus estimate of $0.69 by 73.91 percent. This is a 16.67 percent decrease over earnings of $1.44 per share
Benzinga Newsdesk
PRO
BioMarin Pharmaceutical Lowers FY2026 Adj EPS Guidance from $4.95-$5.15 to $4.85-$5.05 vs $4.43 Est; Raises FY2026 Sales Guidance from $3.325B-$3.425B to $3.825B-$3.925B vs $3.635B Est
Benzinga Newsdesk
PRO
Biomarin Pharmaceutical Q1 Adj. EPS $0.76 Misses $0.79 Estimate, Sales $766.208M Beat $755.610M Estimate
Benzinga Newsdesk
Earnings Scheduled For May 4, 2026
Benzinga Insights
PRO
BioMarin Pharmaceutical Sees FY2026 Sales $3.325B-$3.425B vs $3.507B Est
BioMarin Pharmaceutical (NASDAQ:BMRN) sees FY2026 sales of $3.325 billion-$3.425 billion vs $3.507 billion analyst estimate.
Benzinga Newsdesk
